Table 3.
Chemoprevention clinical practices of providers with regards to their patients with LS.
| Is chemoprevention used frequently in your patients with LS? | ||
|---|---|---|
| n=59 | ||
| n | % | |
| Yes | 35 | 59.3 |
| No | 18 | 30.5 |
| Uncertain, chemoprevention patient use, in any capacity, is outside the purview of my services | 3 | 5.1 |
| Other: | 3 | 5.1 |
| If yes, which dose per day? | ||
| n=39 | ||
| n | % | |
| ≤100 mg | 11 | 28.2 |
| >100 mg - 325 mg | 9 | 23.1 |
| 600 mg | 7 | 1.8 |
| Other (see Supplementary Table 4S ) | 12 | 30.8 |
| Is chemoprevention discussed with your patients with LS? | ||
| n=59 | ||
| n | % | |
| Yes | 40 | 67.8 |
| Yes, I discuss it, but I am not the prescriber | 15 | 25.4 |
| No | 3 | 5.1 |
| Uncertain, chemoprevention is not within the purview of my services | 1 | 1.7 |
| Other | 0 | 0.0 |
| If aspirin has been advised for your LS patient, which of the following scenario applies you: | ||
| n=55 | ||
| n | % | |
| Begin aspirin from commencement of their colonoscopy screening (usually at age 25 years) | 26 | 47.3 |
| Begin aspirin under age 18 years | 2 | 3.6 |
| Begin aspirin at age 18-25y | 6 | 10.9 |
| Begin aspirin over age 25y | 7 | 12.7 |
| All ages would be considered | 4 | 7.3 |
| N/A | 2 | 3.6 |
| Uncertain | 5 | 9.1 |
| Other (see Supplementary Table 5S ) | 3 | 5.5 |
| When your LS patient reaches 50-59 years of age and cardiovascular disease risk is ≥ 10% over the next 10 years, will you recommend low-dose of aspirin? | ||
| n=58 | ||
| n | % | |
| Strongly agree | 23 | 39.7 |
| Agree | 18 | 31.0 |
| Neutral | 6 | 10.3 |
| Disagree | 5 | 8.6 |
| Strongly disagree | 1 | 1.7 |
| Uncertain, in depth chemoprevention discussion is not within the purview of my services | 5 | 8.6 |